Cannabigerol (CBG) is a lesser-known cannabinoid that has been gaining popularity for its potential health benefits. A new study conducted by researchers at Washington State University found that 20 mg of hemp-derived CBG effectively reduced feelings of anxiety in participants at 20, 45, and 60 minutes after ingestion compared to a placebo. The study also indicated that stress ratings decreased at the first time point compared to the placebo. These findings align with survey data showing that a significant number of CBG users consume it to decrease anxiety, with many claiming it is superior to conventional anxiety medications.
The study was a double-blind, placebo-controlled, experimental trial conducted with 34 healthy cannabis users. Participants completed two sessions where they ingested either 20 mg of hemp-derived CBG or a placebo tincture. The researchers then assessed the participants’ mood, stress, anxiety, and other variables at three different time points post-ingestion. Surprisingly, the study found that CBG not only reduced anxiety but also significantly enhanced memory. Participants were able to recall more words after taking CBG, contrary to expectations based on THC’s known effects on memory. The study also found that CBG did not produce cognitive or motor impairments.
While the results of the study are promising, lead researcher Carrie Cuttler emphasizes the need for careful interpretation due to the study’s limitations. The use of experienced cannabis users, the modest dose of CBG, and the study’s remote nature conducted via Zoom may have influenced the findings. Cuttler cautions against making claims that CBG is a miracle drug, stressing the importance of replication and further research to better understand its benefits and safety. She and her team are planning a new clinical trial to replicate their findings and include physiological measures such as heart rate, blood pressure, and cortisol levels.
Despite the promising results of the study, Cuttler stresses the need for further research to build a comprehensive understanding of CBG’s potential benefits. The team plans to extend their research to non-cannabis users and conduct a study on CBG’s effects on menopause symptoms in women. While CBG is becoming increasingly popular and producers are making bold claims about its effects, Cuttler’s study is one of the first to provide evidence supporting some of these claims. Further studies will be essential in determining CBG’s efficacy in reducing feelings of anxiety and stress without the intoxicating effects of THC.
Overall, the study on the effects of CBG on anxiety, stress, and mood is a significant step in understanding the potential benefits of this lesser-known cannabinoid. While the results are promising, more research is needed to confirm and expand on these findings. It is essential to approach claims about the efficacy of CBG cautiously and continue to explore its potential benefits and safety through further studies. Cuttler and her team are committed to ongoing research to provide a more comprehensive understanding of CBG and its potential applications in mitigating anxiety and stress.
